In our current study, StudyR, we found that four (4.2%) (designated as R1 to R4) out of 96 first-degree relatives of CML patients harboured BCR::ABL1 M-BCR, whereas StudyN showed that one (0.5%) (designated as P1) out of 190 subjects in normal population harboured BCR::ABL1 M-BCR [31]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.